Intellectus Partners LLC Raises Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)

Intellectus Partners LLC grew its stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL) by 1.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 887,283 shares of the company’s stock after buying an additional 10,650 shares during the period. AbCellera Biologics makes up 1.5% of Intellectus Partners LLC’s portfolio, making the stock its 10th biggest position. Intellectus Partners LLC owned approximately 0.31% of AbCellera Biologics worth $5,066,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. National Bank of Canada FI raised its position in AbCellera Biologics by 392.7% in the 3rd quarter. National Bank of Canada FI now owns 6,085 shares of the company’s stock valued at $27,000 after buying an additional 4,850 shares during the last quarter. Pacifica Partners Inc. grew its position in shares of AbCellera Biologics by 82.9% in the 4th quarter. Pacifica Partners Inc. now owns 4,820 shares of the company’s stock valued at $28,000 after buying an additional 2,185 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of AbCellera Biologics in the 3rd quarter valued at about $30,000. China Universal Asset Management Co. Ltd. grew its position in shares of AbCellera Biologics by 96.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,423 shares of the company’s stock valued at $34,000 after buying an additional 3,638 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. bought a new stake in shares of AbCellera Biologics in the 3rd quarter valued at about $48,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stifel Nicolaus cut their target price on AbCellera Biologics from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 21st. Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $9.00 price objective for the company in a research note on Thursday, February 22nd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, AbCellera Biologics presently has a consensus rating of “Buy” and a consensus target price of $15.86.

AbCellera Biologics Stock Performance

Shares of ABCL traded up $0.13 during trading hours on Friday, reaching $3.76. 1,369,561 shares of the company’s stock traded hands, compared to its average volume of 1,075,373. AbCellera Biologics Inc. has a 12 month low of $3.62 and a 12 month high of $8.05. The firm’s 50 day simple moving average is $4.56 and its 200-day simple moving average is $4.80.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). AbCellera Biologics had a negative return on equity of 12.36% and a negative net margin of 384.99%. The business had revenue of $9.18 million for the quarter, compared to analysts’ expectations of $9.58 million. As a group, equities analysts forecast that AbCellera Biologics Inc. will post -0.66 earnings per share for the current fiscal year.

AbCellera Biologics Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.